CD8A and neoplasm: As per Wu et al., 2021, DAC alone led to modest tumor control, but DAC + anti-PD-1 therapy produced synergistic tumor regression, prolonged survival, and enhanced granzyme B+ CD8+ cytotoxic T-cell activation [73].